ERBB2 and adenocarcinoma: Here, we found a possibly discriminating cell-surface biomarker of HER2 that might triage adenocarcinoma or adenosquamous uterine cervix cancers to a HER2-targeted radiopharmaceutical like the thorium-227 trastuzumab-linked conjugate.